AU2018374285B2 - Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation - Google Patents

Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation Download PDF

Info

Publication number
AU2018374285B2
AU2018374285B2 AU2018374285A AU2018374285A AU2018374285B2 AU 2018374285 B2 AU2018374285 B2 AU 2018374285B2 AU 2018374285 A AU2018374285 A AU 2018374285A AU 2018374285 A AU2018374285 A AU 2018374285A AU 2018374285 B2 AU2018374285 B2 AU 2018374285B2
Authority
AU
Australia
Prior art keywords
hct
subject
alat
dose
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018374285A
Other languages
English (en)
Other versions
AU2018374285A1 (en
Inventor
Gautam BAHETI
John Roberts
Marc UKNIS
Christine VOIGT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring LLC
Original Assignee
CSL Behring LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring LLC filed Critical CSL Behring LLC
Publication of AU2018374285A1 publication Critical patent/AU2018374285A1/en
Application granted granted Critical
Publication of AU2018374285B2 publication Critical patent/AU2018374285B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2018374285A 2017-12-01 2018-11-30 Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation Active AU2018374285B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593446P 2017-12-01 2017-12-01
US62/593,446 2017-12-01
US201862729376P 2018-09-10 2018-09-10
US62/729,376 2018-09-10
PCT/US2018/063179 WO2019108865A1 (en) 2017-12-01 2018-11-30 Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation

Publications (2)

Publication Number Publication Date
AU2018374285A1 AU2018374285A1 (en) 2020-07-02
AU2018374285B2 true AU2018374285B2 (en) 2024-06-27

Family

ID=64734181

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018374285A Active AU2018374285B2 (en) 2017-12-01 2018-11-30 Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation

Country Status (13)

Country Link
US (2) US11857610B2 (https=)
EP (2) EP4321220B1 (https=)
JP (2) JP2021505545A (https=)
AU (1) AU2018374285B2 (https=)
DK (1) DK3716998T3 (https=)
ES (2) ES2975208T3 (https=)
FI (1) FI3716998T3 (https=)
HR (1) HRP20240475T8 (https=)
HU (1) HUE066011T2 (https=)
PL (1) PL3716998T3 (https=)
PT (1) PT3716998T (https=)
SI (1) SI3716998T1 (https=)
WO (1) WO2019108865A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
WO2023056075A1 (en) * 2021-10-01 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reduced toxicity in transplantation using janus kinase (jak) inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457070B2 (en) * 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US20090118162A1 (en) 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10，顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
CA2798518A1 (en) * 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
EP3628327A1 (en) * 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN110551223A (zh) 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
ES2799153T3 (es) 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante
WO2017117558A1 (en) 2015-12-31 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications

Also Published As

Publication number Publication date
HRP20240475T8 (hr) 2024-08-02
SI3716998T1 (sl) 2024-05-31
EP3716998B1 (en) 2024-01-10
PT3716998T (pt) 2024-04-09
EP4321220B1 (en) 2025-10-29
DK3716998T3 (da) 2024-04-02
JP2021505545A (ja) 2021-02-18
JP2024001191A (ja) 2024-01-09
PL3716998T3 (pl) 2024-06-24
US20210008182A1 (en) 2021-01-14
US20240238395A1 (en) 2024-07-18
US11857610B2 (en) 2024-01-02
HUE066011T2 (hu) 2024-07-28
ES3059603T3 (en) 2026-03-23
HRP20240475T1 (hr) 2024-07-05
AU2018374285A1 (en) 2020-07-02
WO2019108865A1 (en) 2019-06-06
EP4321220A3 (en) 2024-03-20
EP4321220A2 (en) 2024-02-14
FI3716998T3 (fi) 2024-04-16
EP3716998A1 (en) 2020-10-07
ES2975208T3 (es) 2024-07-04

Similar Documents

Publication Publication Date Title
US10913792B2 (en) Treatment for rheumatoid arthritis
US20240287198A1 (en) Anti-cd40 antibodies for use in prevention of graft rejection
JP2024167278A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
US20120269806A1 (en) Methods of inducing tolerance
US20240238395A1 (en) Methods for Reducing Risk of Onset of Acute Graft Versus Host Disease After Hematopoeitic Cell Transplantation
KR20210120048A (ko) 다발성 골수종의 치료 방법
JP2023531251A (ja) 抗ｃｄ２抗体
KR20220008305A (ko) 다발성 골수종을 치료하기 위해서 항-cd38 항체를 투여하는 방법
US20170121419A1 (en) Anti-human Chemokine (C-C motif) Receptor 4 Immunotoxins
JP2024534926A (ja) 寛容性を誘導するための方法及び組成物
HK40106704A (en) A1at for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation
US20250228942A1 (en) Methods for activation and expansion of engineered natural killer cells and combinations with antibodies
CA3195260A1 (en) Fusion proteins for the treatment of disease
KR20220104201A (ko) 조혈 줄기 세포 이식과 관련된 특발성 폐렴 증후군 (ips) 및/또는 모세혈관 누출 증후군 (cls) 및/또는 생착 증후군 (es) 및/또는 체액 과부하 (fo)를 치료 및/또는 예방하는 방법
US20240335545A1 (en) Methods of Treating Graft Versus Host Disease
Snowden et al. Haemopoietic Stem Cell Transplantation for Rheumatoid Arthritis—World Experience and Future Trials
Chen Highlights in Graft-vs-Host Disease From the 63rd American Society of Hematology Annual Meeting and Exposition
JP2026513936A (ja) 自己免疫疾患の処置のための方法
JP2025519163A (ja) Ｃｄ３８に結合する融合タンパク質の投与
WO2025207763A1 (en) Method and composition for inducing tolerance of transplanted organ or tissue
TW202535463A (zh) Ａｎｃａ相關血管炎之治療
TW202509210A (zh) 多受體自然殺手細胞
HK40049374A (en) Use of anti-ccr5 antibodies in graft versus host disease
Chen et al. Highlights in Graft-vs-Host Disease From the 2021 Transplantation & Cellular Therapy (TCT) Meetings of the ASTCT and the CIBMTR

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)